Red-blood-cell manufacturing methods and storage solutions differentially induce pulmonary cell activation.

blood processing cytokine and chemokine production extracellular vesicles mechanical ventilation thrombin generation

Journal

Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 24 07 2019
revised: 07 02 2020
accepted: 23 02 2020
pubmed: 14 3 2020
medline: 1 12 2020
entrez: 14 3 2020
Statut: ppublish

Résumé

Red-blood-cell (RBC) transfusion is associated with lung injury, which is further exacerbated by mechanical ventilation. Manufacturing methods of blood products differ globally and may play a role in the induction of pulmonary cell activation through alteration of the immunomodulatory property of the products. Here, the effect of different manufacturing methods on pulmonary cell activation was investigated in an in vitro model of mechanical ventilation. Pulmonary type II cells were incubated with supernatant from fresh and old RBC products obtained via whole blood filtration (WBF), red cell filtration (RCF), apheresis-derived (AD) or whole blood-derived (WBD) methods. Lung cells were subjected to 25% stretch for 24 h. Controls were non-stretched or non-incubated cells. Fresh but not old AD products and WBF products induce lung cell production of pro-inflammatory cytokines and chemokines, which was not observed with WBD or RCF products. Effects were associated with an increased amount of platelet-derived vesicles and an increased thrombin-generating capacity. Mechanical stretching of lung cells induced more severe cell injury compared to un-stretched controls, including alterations in the cytoskeleton, which was further augmented by incubation with AD products. In all read-out parameters, RCF products seemed to induce less injury compared to the other products. Our findings show that manufacturing methods of RBC products impact pulmonary cell activation, which may be mediated by the generation of vesicles in the product. We suggest RBC manufacturing method may be an important factor in understanding the association between RBC transfusion and lung injury.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
Red-blood-cell (RBC) transfusion is associated with lung injury, which is further exacerbated by mechanical ventilation. Manufacturing methods of blood products differ globally and may play a role in the induction of pulmonary cell activation through alteration of the immunomodulatory property of the products. Here, the effect of different manufacturing methods on pulmonary cell activation was investigated in an in vitro model of mechanical ventilation.
MATERIALS AND METHODS METHODS
Pulmonary type II cells were incubated with supernatant from fresh and old RBC products obtained via whole blood filtration (WBF), red cell filtration (RCF), apheresis-derived (AD) or whole blood-derived (WBD) methods. Lung cells were subjected to 25% stretch for 24 h. Controls were non-stretched or non-incubated cells.
RESULTS RESULTS
Fresh but not old AD products and WBF products induce lung cell production of pro-inflammatory cytokines and chemokines, which was not observed with WBD or RCF products. Effects were associated with an increased amount of platelet-derived vesicles and an increased thrombin-generating capacity. Mechanical stretching of lung cells induced more severe cell injury compared to un-stretched controls, including alterations in the cytoskeleton, which was further augmented by incubation with AD products. In all read-out parameters, RCF products seemed to induce less injury compared to the other products.
CONCLUSIONS CONCLUSIONS
Our findings show that manufacturing methods of RBC products impact pulmonary cell activation, which may be mediated by the generation of vesicles in the product. We suggest RBC manufacturing method may be an important factor in understanding the association between RBC transfusion and lung injury.

Identifiants

pubmed: 32166810
doi: 10.1111/vox.12911
pmc: PMC7497002
doi:

Substances chimiques

Cytokines 0
Thrombin EC 3.4.21.5

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

395-404

Subventions

Organisme : Canadian Blood Services Intramural Grant program
ID : 2015IG-JA

Informations de copyright

© 2020 The Authors. Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion.

Références

Crit Care Med. 2008 Nov;36(11):3080-4
pubmed: 18824899
Vox Sang. 2017 Apr;112(3):268-278
pubmed: 28220494
J Am Coll Surg. 2012 Apr;214(4):648-55; discussion 656-7
pubmed: 22342784
Transfusion. 2015 Sep;55(9):2184-96
pubmed: 26032769
Blood Adv. 2018 Sep 25;2(18):2296-2306
pubmed: 30217795
Vox Sang. 2015 May;108(4):350-8
pubmed: 25678039
Sci Rep. 2017 Jul 26;7(1):6522
pubmed: 28747771
Transfusion. 2013 Aug;53(8):1744-54
pubmed: 23228139
Vox Sang. 2016 Jul;111(1):22-32
pubmed: 26918437
Respiration. 2007;74(5):579-85
pubmed: 17435381
N Engl J Med. 2017 Nov 9;377(19):1858-1867
pubmed: 28952891
Transfusion. 2004 Oct;44(10):1468-74
pubmed: 15383020
Transfus Med Hemother. 2016 Jan;43(1):19-26
pubmed: 27022319
Int Immunopharmacol. 2018 Feb;55:98-104
pubmed: 29241160
Transfusion. 2013 Oct;53(10):2258-67
pubmed: 23320518
Transfusion. 2015 Apr;55(4):709-18
pubmed: 25371300
Blood Transfus. 2019 Jan;17(1):27-52
pubmed: 30653459
Int J Mol Sci. 2017 Jun 16;18(6):
pubmed: 28621719
Ann Transl Med. 2018 Jan;6(2):23
pubmed: 29430440
Transfus Med Hemother. 2018 May;45(3):185-193
pubmed: 29928174
Transfus Apher Sci. 2017 Apr;56(2):254-260
pubmed: 28363591
Vox Sang. 2011 Jan;100(1):122-8
pubmed: 21175662
Transfusion. 2014 Oct;54(10):2534-43
pubmed: 24805193
Blood Rev. 2018 Jan;32(1):1-7
pubmed: 28823763
Mol Cancer. 2015 Mar 11;14:58
pubmed: 25881295
Transfusion. 2018 Aug;58(8):1992-2002
pubmed: 29624679
Lancet. 2013 Sep 14;382(9896):984-94
pubmed: 23642914
Transfusion. 2016 Sep;56(9):2173-83
pubmed: 27301995
Transfusion. 2017 Nov;57(11):2701-2711
pubmed: 28766731
Platelets. 2017 May;28(3):222-227
pubmed: 27928930
Crit Care. 2007;11(3):R63
pubmed: 17553147
Anesthesiology. 2010 Jul;113(1):92-103
pubmed: 20508493
Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):313-20
pubmed: 24311376
Lancet Haematol. 2016 May;3(5):e246-54
pubmed: 27132699
Blood. 2012 Feb 16;119(7):1757-67
pubmed: 22117051
Transfus Apher Sci. 2016 Aug;55(1):92-104
pubmed: 27452642
Transfus Med Rev. 2018 Jan;32(1):16-27
pubmed: 28864336

Auteurs

Mathijs R Wirtz (MR)

Laboratory of Experimental Intensive Care and Anesthesiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Department of Intensive Care Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Ruqayyah J Almizraq (RJ)

Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.

Nina C Weber (NC)

Laboratory of Experimental Intensive Care and Anesthesiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Philip J Norris (PJ)

Blood Systems Research Institute, San Francisco, CA, USA.
Departments of Laboratory Medicine and Medicine, University of California, San Francisco, CA, USA.

Suchitra Pandey (S)

Department of Laboratory Medicine, University of California, San Francisco, CA, USA.
Blood Centers of the Pacific (member of Blood Systems), San Francisco, CA, USA.

Philip C Spinella (PC)

Department of Pediatrics, Division of Critical Care, Washington University in St Louis, St Louis, MO, USA.

Jennifer A Muszynski (JA)

Department of Pediatrics, Division of Critical Care Medicine, Nationwide Children's Hospital, Columbus, OH, USA.

Jason P Acker (J)

Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada.
Centre for Innovation, Canadian Blood Services, Edmonton, AB, Canada.

Nicole P Juffermans (NP)

Laboratory of Experimental Intensive Care and Anesthesiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Department of Intensive Care Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH